Related Experiment Video
Updated: Nov 10, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.2K
Peptide-Functionalized Nanoparticles-Encapsulated Cyclin-Dependent Kinases Inhibitor Seliciclib in Transferrin
Guan Zhen He1, Wen Jen Lin1,2
1School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
Nanomaterials (Basel, Switzerland)
|April 3, 2021
Summary
Targeted nanoparticles loaded with seliciclib show enhanced cancer cell uptake and efficacy. T7 peptide decoration improves delivery to transferrin receptor-overexpressing cancer cells, increasing drug sensitivity.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapeutics
Background:
- Seliciclib is a cyclin-dependent kinases (CDKs) inhibitor with potential in cancer therapy.
- Cancer cells often overexpress transferrin receptors (TfRs), presenting a target for drug delivery.
- Targeted delivery systems can enhance nanoparticle internalization and drug efficacy.
Purpose of the Study:
- To develop T7 peptide-decorated nanoparticles (NPs) for targeted delivery of seliciclib.
- To evaluate the cellular uptake and anti-cancer efficacy of these targeted NPs.
- To assess the drug sensitivity of cancer cells treated with seliciclib-loaded NPs.
Main Methods:
- Synthesized poly(d,l-lactide-co-glycolide)-poly(ethylene glycol)-maleimide (PLGA-PEG-maleimide) copolymer.
- Prepared seliciclib-encapsulated NPs and decorated them with T7 peptide.
- Assessed cellular uptake in cancer cell lines with varying TfR expression (MDA-MB-231, SKOV-3, U87-MG).
- Determined the inhibitory concentration 50 (IC50) values for free and encapsulated seliciclib.
Main Results:
- T7 peptide-modified NPs demonstrated superior cellular uptake in TfR-high expressing cancer cells.
- Uptake efficiency followed the order: MDA-MB-231 > SKOV-3 > U87-MG.
- SKOV-3 and U87-MG cells showed increased sensitivity to seliciclib encapsulated in T7-decorated NPs.
- Encapsulation led to lower IC50 values compared to free seliciclib.
Conclusions:
- T7 peptide-mediated targeting enhances nanoparticle delivery to TfR-overexpressing cancer cells.
- Seliciclib-loaded, T7-decorated NPs exhibit improved anti-cancer efficacy.
- This targeted nanodelivery system holds promise for seliciclib-based cancer therapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:34Inhibition of Cdk Activity
5.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
02:38Mitogens and the Cell Cycle
7.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K